Categories October Surprise 2024 Soluble Fas ligand prevents disease progression in glaucoma … – BioWorld Post author By Post date May 6, 2024 Schepens Eye Research Institute presented new preclinical data on its AAV2.sFasL gene therapy, an adeno-associated virus (AVV2) encoding soluble Fas ligand (sFasL) for the potential prevention of glaucoma.